# Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML

> **NCT07091006** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Relapse Leukemia

## Interventions

- **DRUG:** VAH

## Key facts

- **NCT ID:** NCT07091006
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07091006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07091006, "Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07091006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*